As the Thanksgiving holiday approaches, the US FDA followed up one massive week of approvals with another, giving the greenlight three new molecular entities (NME) and a slew of supplemental indications. Here's your news in brief:
But more importantly, the agency finally unveiled its biologic suffix naming convention, approving the first two novel biologics with a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?